Skip to main content
Medical information Clinical review pending

Genetic Testing

Mucopolysaccharidosis MPS Screen Urine Test

A urine test to screen for Mucopolysaccharidoses (MPS), a group of inherited metabolic disorders. Early detection helps with management and treatment.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
10 ml (5 ml minimum) of first morning urine collected in a sterile, screw-capped container. Do not add preservatives.
Results
Report typically available the next day if the sample is received by 4 pm. Confirm with the laboratory for current turnaround times.
Preparation
Collect the first morning urine sample. Provide a brief clinical and drug history with the sample.
Test priceKSh 819

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Mucopolysaccharidosis MPS Screen Urine Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Individuals with symptoms suggestive of MPS (e.g., developmental delays, skeletal abnormalities, joint stiffness, organ enlargement).
  • ✓Family history of MPS or related metabolic disorders.
  • ✓Screening in individuals with unexplained developmental or physical abnormalities.
  • ✓Monitoring of patients diagnosed with MPS (confirm with the laboratory).
02

In plain language

What this test helps you understand

This test aids in the initial screening for Mucopolysaccharidoses (MPS), a group of inherited metabolic disorders. It helps identify elevated levels of glycosaminoglycans (GAGs) in the urine, which are characteristic of these conditions. Early detection facilitates timely diagnosis and management.
The Mucopolysaccharidosis (MPS) Screen Urine Test is used to help identify MPS, which are inherited metabolic disorders. These conditions occur when the body lacks the necessary enzymes to break down complex sugars called glycosaminoglycans (GAGs). This breakdown process is essential for normal bodily function.

This test measures the levels of GAGs in a urine sample. Elevated levels can suggest the presence of an MPS disorder. Early diagnosis is important because it allows for timely intervention and management strategies, potentially improving the quality of life for individuals affected by MPS.

If the screening test indicates abnormal GAG levels, further diagnostic testing is usually recommended to confirm the diagnosis and identify the specific type of MPS.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationCollect the first morning urine sample. Provide a brief clinical and drug history with the sample.
Sample10 ml (5 ml minimum) of first morning urine collected in a sterile, screw-capped container. Do not add preservatives.
MethodologyThe test involves measuring the levels of glycosaminoglycans (GAGs) in the urine sample. Specific methods may vary; confirm with the laboratory.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This is a screening test. Elevated GAG levels are not specific to MPS and can be seen in other conditions. A negative result does not completely rule out MPS. Further testing is required for confirmation.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

MPS are a group of rare, inherited metabolic disorders caused by the absence or malfunctioning of specific enzymes needed to break down complex sugars called glycosaminoglycans (GAGs).
Early diagnosis allows for timely management and treatment, which can help slow disease progression and improve the quality of life for affected individuals.
An abnormal result indicates elevated levels of GAGs in the urine. This suggests the possibility of an MPS disorder and requires further diagnostic testing for confirmation.
No, this is a screening test. Further tests, such as enzyme activity assays or genetic testing, are needed to confirm a diagnosis of MPS.
The first morning urine sample should be collected in a sterile container provided by the lab. Do not add any preservatives.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp